Is The Ketek Scandal Good For Big Pharma?
This article was originally published in The Pink Sheet Daily
Executive Summary
Follow-on biologics legislation could be a tougher sell because of distrust of FDA on the Energy and Commerce Committee.
You may also be interested in...
Wyeth Plans To Market Second-Generation Ketolide In Asia Pacific Region
HONG KONG - Wyeth plans to market a second-generation ketolide in the Asia Pacific region, noting that serious side effects associated with the first generation of the new type of antibiotic have not surfaced
House Panel Considers Citing FDA For Contempt In Ketek Investigation
FDA fails to submit subpoenaed documents in House investigation into possible clinical trial fraud.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.